Evaluation of the effects of MC-1 [pyridoxal phosphate] alone and in combination with an ACE inhibitor on ambulatory blood pressure and metabolic function in hypertensive patients with type 2 diabetes mellitus

Trial Profile

Evaluation of the effects of MC-1 [pyridoxal phosphate] alone and in combination with an ACE inhibitor on ambulatory blood pressure and metabolic function in hypertensive patients with type 2 diabetes mellitus

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2009

At a glance

  • Drugs Lisinopril; Lisinopril/pyridoxal phosphate; Pyridoxal phosphate
  • Indications Hypertension; Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms MATCHED
  • Sponsors Medicure
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Apr 2008 Interim results were reported at ATVB 2008, according to a Medicure media release.
    • 23 Aug 2007 The expected completion date for this trial is now 1 Jul 2005.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top